Picture loading failed.

Pre-Made Valanafusp biosimilar, Whole mAb Fusion, Anti-INSR Antibody: Anti-CD220/HHF5 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Valanafusp alpha is a BBB-penetrating form of IDUA, and is designed to deliver the IDUA enzyme to brain cells to reverse the accumulation of heparan sulfate (HS) GAGs and lysosomal inclusions. The primary therapeutic goal of valanafusp alpha therapy is stabilization of cognitive decline in severe MPSI.

Order information


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-608-1mg 1mg Inquiry
GMP-Bios-ab-608-10mg 10mg Inquiry
GMP-Bios-ab-608-100mg 100mg Inquiry
GMP-Bios-ab-608-xmg >100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Pre-Made Valanafusp biosimilar, Whole mAb Fusion, Anti-INSR Antibody: Anti-CD220/HHF5 therapeutic antibody
INN Name Valanafusp
TargetINSR
FormatWhole mAb Fusion
Derivation
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusActive
100% SI StructureNone
99% SI Structure5kqv:PQ:CD/4zxb:CD
95-98% SI Structure3loh:CD/2dtg:CD/3w14:CD:PQ
Year Proposed2017
Year Recommended2018
CompaniesArmaGen Technologies
Conditions Approvedna
Conditions ActiveMucopolysaccharidosis I
Conditions Discontinuedna
Development Techna